




# Patient networksAnna Goldenberg<br/>andin cancer:Anna Goldenberg<br/>andandThe Goldenberg Labaplatform for dataThe Goldenberg Labintegration


## Outline

- Data integration problem setup
- Patient network representation why and how
- Similarity Network Fusion novel integration method
- Network driven analysis:
  - Cancer heterogeneity
  - Differential feature selection
- Missing data
  - o Random entries
  - o Patients
- Taking networks further:
  - Survival analysis (novel formulation)
    - Personalized medicine






### How to combine?



### How to combine?





### Issues


 Large number of measurements, small sample sizes (p>>n)

 Need to integrate common and complementary information

 Not all measurements can be mapped to the same unit (gene)





























Patient similarity: 
$$W(i,j) = exp(\frac{\rho(x_i,x_j)^2}{\eta\xi_{ij}^2})$$

Adjacency matrix:


$$P(i,j) = \frac{W(i,j)}{\sum_{k \in V} W(i,k)}$$





1) 
$$\mathcal{W}(i,j) = \begin{cases} W(i,j) \text{ if } x_j \in KNN(x_i) \\ 0 \text{ otherwise} \end{cases}$$


Sparsification

2) 
$$\mathcal{P}(i,j) = \frac{\mathcal{W}(i,j)}{\sum_{x_k \in KNN(x_i)} \mathcal{W}(i,k)}$$











Sample Similarity Networks




2.

mRNA-based

DNA Methylation-based




2.




Sample Similarity Networks

2.

**Fusion Iterations** 



2.



### **Network Fusion**

Fusing 2 networks:

$$P_{t+1}^{(1)} = \mathcal{P}^{(1)} \times (P_t^{(2)}) \times (\mathcal{P}^{(1)})'$$
$$P_{t+1}^{(2)} = \mathcal{P}^{(2)} \times (P_t^{(1)}) \times (\mathcal{P}^{(2)})'$$

Fusing m networks:

$$P_{t+1}^{(i)} = \mathcal{P}^{(i)} \times \left(\frac{1}{m-1} \sum_{j \neq i} P_t^{(j)}\right) \times (\mathcal{P}^{(i)})' + \eta I$$

## Experiments

### Data:

5 TCGA cancers METABRIC (Large Breast Cancer db)

### **Comparative Methods:**

Concatenation iCluster PDSB Multiple kernel learning


### Criteria:

-log<sub>10</sub>(log rank pvalue)


Silhouette score (cluster homogeneity)

Running time

### Simulation 1 – complementarity




### Simulation 1 convergence




20% of patients are mislabeled

## Simulation 2 - removing noise

**Gaussian Noise** 



### Simulation 2 - removing noise




### **TCGA** Data


Cancer Type	Patients	mRNA	Methylation	miRNA	Controls	
					<u>mRNA</u>	Methylation
GBM	215	12,042	1,491	534	10	-
BIC	105	17,814	23,094	1,046	63	27
KRCCC	124	20,532	24,976	1,046	68	199
LSCC	105	12,042	27,578	1,046	-	27
COAD	92	17814	27578	705	19	37

## Case study: Glioblastoma


## DNA methylation data


#### mRNA expression






### miRNA expression







## Case study: Glioblastoma





### Clinical properties of the subtypes







### Clinical properties of the subtypes







### Clinical properties of the subtypes








### Biological characterization of the subtypes



### **Feature Selection**


### Standard t-test Differential analysis



### **Feature Selection**


### Standard t-test Differential analysis


### Network-based NMI Differential analysis



Bo Wang


### Gene Pre-selection in GBM






Genes are ordered by significance of the differential values between tumor and normal Bo Wang

### Gene Pre-selection in GBM




Genes are ordered by significance of the differential values between tumor and normal Bo Wang

### Gene Pre-selection in GBM




Genes are ordered by significance of the differential values between tumor and normal Bo Wang

### Gene pre-selection across cancers



Bo Wang


## Clustering of the network



## Patient networks framework advantages

- Creates a unified view of patients based on multiple heterogeneous sources
- ✓ Integrates gene and non-gene based data
- ✓ No need to do gene pre-selection
- $\checkmark$  Robust to different types of noise
- ✓ Scalable

### Patient networks



### Breast Cancer (METABRIC example)

### CNV and expression data Discovery: 997 patients Validation: 995 patients

Nature,	
2012	
	-

	PAM50 (5 clusters)	iCluster (10 clusters)	SNF (5 clusters)	SNF (10 clusters)
P value discovery cohort	3.0 × 10 <sup>-9</sup>	1.2 × 10 <sup>-14</sup>	$6.10 \times 10^{-11}$	3.31 × 10 <sup>-12</sup>
P value validation cohort	1.7 × 10 <sup>-9</sup>	2.9 × 10 <sup>-11</sup>	5.12 × 10 <sup>-13</sup>	7.86 × 10 <sup>-12</sup>
CI discovery cohort	0.560	0.621	0.638	0.638
CI validation cohort	0.551	0.605	0.633	0.633
established				

### Breast Cancer (METABRIC example)


### CNV and expression data Discovery: 997 patients Validation: 995 patients


Nature,	
2012	
	_


	PAM50 (5 clusters)	iCluster (10 clusters)	SNF (5 clusters)	SNF (10 clusters)	
P value discovery cohort	3.0 × 10 <sup>-9</sup>	1.2 × 10 <sup>-14</sup>	$6.10 \times 10^{-11}$	3.31 × 10 <sup>-12</sup>	
P value validation cohort	1.7 × 10 <sup>-9</sup>	2.9 × 10 <sup>-11</sup>	5.12 × 10 <sup>-13</sup>	7.86 × 10 <sup>-12</sup>	
CI discovery cohort	0.560	0.621	0.638	0.638	
CI validation cohort	0.551	0.605	0.633	0.633	
established					

So how many subtypes are there really in breast cancer?

## Predicting using the network







### Predicting using the network

Cox objective 
$$lp(z) = \sum_{i=1}^{n} \delta_i \left( \mathbf{X}_i^T z - \log \left( \sum_{j \in \mathbf{R}(t_i)} \exp(\mathbf{X}_j^T z) \right) \right)$$

### Predicting using the network

Cox objective 
$$lp(z) = \sum_{i=1}^{n} \delta_i \left( \mathbf{X}_i^T z - \log \left( \sum_{j \in \mathbf{R}(t_i)} \exp(\mathbf{X}_j^T z) \right) \right)$$

Our network-regularized objective

$$lp(z) = \sum_{i=1}^{n} \delta_{i} \left( X_{i}^{T} z - \log \left( \sum_{j \in \mathbf{R}(t_{i})} \exp(X_{j}^{T} z) \right) \right) - \lambda \sum_{i} \sum_{j} (X_{i}^{T} z - X_{j}^{T} z)^{2} w_{ij}$$

### Predicting using the network Breast Cancer (METABRIC example)

